Clinical trials - central venous thrombosis
Why anticoagulation?
- prevent thrombus growth
- facilitate recanalization
- prevent recurrent VTE events
Guidelines
AHA/ASA & European
- parental AC w/ low molecular weight heparin over unfractionated during the acute phase
- transition to oral VKAs for 3-12 months ISO transient risk factors or indefinitely ISO chronic major risk factors
Clinical trials
- DOACs in CVT
RESPECT CVT (2019)
- same benefit dabigatran vs warfarin
EINSTEIN JR (2020)
- same benefit rivaroxaban vs warfarin
ACTION CVT (2022)
- same benefit DOACs vs warfarin
SECRET (2023)
- same benefit rivaroxaban vs warfarin
EXCOA-CVT
- coming
